Safety and efficacy of Sacubitril/Valsartan in blood pressure control of dialysis patients
Phase 1
- Conditions
- Health Condition 1: N186- End stage renal disease
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients declared as CKD 5D
Aged >18 years
Resistant hypertension
Non oliguric
Definitions
CKD 5D- defined as hemodialysis dependence since last 3 months prior to screening
Resistant hypertension- defined as uncontrolled hypertension SBP > 140 mm Hg or DBP >90 mm Hg despite use of 3 or more antihypertensive drugs including a diuretic
Non oliguric- defined as urine output more than 200 ml per day
Exclusion Criteria
Serum potassium >5.5 mg/dl
Not giving consent
History of angioedema
History of intolerance to ACE-inhibitors/ ARBs
Associated heart failure with reduced ejection fraction
Alanine aminotransferase or Aspartate aminotransferase >2 times the upper limit of the normal range
Not willing for thrice a week hemodialysis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The safety of Sacubitril/Valsartan in CKD 5D patientsTimepoint: at the end of week-1/2/4/8/12
- Secondary Outcome Measures
Name Time Method To study efficacy of Sacubitril/Valsartan in control of resistant hypertension in CKD 5D patientsTimepoint: at the end of 3 months